Separately, Zacks Investment Research upgraded NOVOZYMES A/S/S from a sell rating to a hold rating in a report on Saturday, August 10th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $54.00.
Shares of OTCMKTS NVZMY opened at $41.02 on Monday. NOVOZYMES A/S/S has a twelve month low of $40.38 and a twelve month high of $55.84. The company has a current ratio of 1.22, a quick ratio of 0.71 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $12.24 billion, a price-to-earnings ratio of 23.44, a price-to-earnings-growth ratio of 1.93 and a beta of 0.70. The business has a 50 day simple moving average of $45.43 and a 200-day simple moving average of $46.23.
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry.
Featured Story: Different Options Trading Strategies
Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.